DeFronzo, Ralph A.

Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls

Platform, B. G., Flannick, J., DiscovEHR Collaboration, CHARGE, LuCamp, ProDiGY, GoT2D, ESP, SIGMA-T2D, T2D-GENES, et al. (2019) · Nature

Genetic Associations and EpidemiologyGenomics and Rare Diseases

Cited by 304

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 297

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 293

Dysfunctional fat cells, lipotoxicity and type 2 diabetes

Defronzo, R. A. (2004) · International Journal of Clinical Practice

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 236

Role of adiponectin in human skeletal muscle bioenergetics

Civitarese, A. E., Ukropcova, B., Carling, S., Hulver, M., DeFronzo, R. A., Mandarino, L., Ravussin, E., & Smith, S. R. (2006) · Cell Metabolism

Adipose Tissue and MetabolismMetabolism, Diabetes, and Cancer

Cited by 234

Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes

DeFronzo, R. A., Inzucchi, S., Abdul-Ghani, M., & Nissen, S. E. (2019) · Diabetes and Vascular Disease Research

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 223

Combination therapy with GLP ‐1 receptor agonist and SGLT2 inhibitor

DeFronzo, R. A. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 192

Roles of Glucose Transport and Glucose Phosphorylation in Muscle Insulin Resistance of NIDDM

Bonadonna, R. C., Bonora, E., Prato, S. D., Saccomani, M. P., Cobelli, C., Natali, A., Frascerra, S., Pecori, N., Ferrannini, E., Bier, D., et al. (1996) · Diabetes

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 191

Pharmacologic Therapy for Type 2 Diabetes Mellitus

DeFronzo, R. A. (2000) · Annals of Internal Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 176

Regulation of hepatic glucose metabolism in humans

DeFronzo, R. A., & Ferrannini, E. (1987) · Diabetes/Metabolism Reviews

Pancreatic function and diabetesMetabolism, Diabetes, and Cancer

Cited by 167

GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

Alkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R., & Shulman, G. I. (2020) · Expert Opinion on Investigational Drugs

Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Cited by 162

Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans

Bonadonna, R. C., Groop, L. C., Zych, K., Shank, M., & DeFronzo, R. A. (1990) · American Journal of Physiology-Endocrinology and Metabolism

Lipid metabolism and biosynthesisLipid metabolism and disorders

Cited by 149

Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance

Abdul-Ghani, M. A., Muller, F. L., Liu, Y., Chavez, A. O., Balas, B., Zuo, P., Chang, Z., Tripathy, D., Jani, R., Molina-Carrion, M., et al. (2008) · American Journal of Physiology-Endocrinology and Metabolism

Mitochondrial Function and PathologyMetabolism, Diabetes, and Cancer

Cited by 140

The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes

Abdul‐Ghani, M. A., Lyssenko, V., Tuomi, T., DeFronzo, R. A., & Groop, L. (2010) · Diabetes/Metabolism Research and Reviews

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 139

Reduction in Reactive Oxygen Species Production by Mitochondria From Elderly Subjects With Normal and Impaired Glucose Tolerance

Ghosh, S., Lertwattanarak, R., Lefort, N., Molina-Carrion, M., Joya-Galeana, J., Bowen, B. P., Garduno-Garcia, J. D. J., Abdul-Ghani, M., Richardson, A., DeFronzo, R. A., et al. (2011) · Diabetes

Mitochondrial Function and PathologyAdipose Tissue and Metabolism

Cited by 128

Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance

Kanat, M., Mari, A., Norton, L., Winnier, D., DeFronzo, R. A., Jenkinson, C., & Abdul-Ghani, M. A. (2012) · Diabetes

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 122

Insulin-induced hexokinase II expression is reduced in obesity and NIDDM.

Pendergrass, M., Koval, J., Vogt, C., Yki-Jarvinen, H., Iozzo, P., Pipek, R., Ardehali, H., Printz, R., Granner, D., DeFronzo, R. A., et al. (1998) · Diabetes

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 119

Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation

Pratipanawatr, W., Pratipanawatr, T., Cusi, K., Berria, R., Adams, J. M., Jenkinson, C. P., Maezono, K., DeFronzo, R. A., & Mandarino, L. J. (2001) · Diabetes

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 118

Prevention of Diabetes With Pioglitazone in ACT NOW

DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., et al. (2013) · Diabetes

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 109

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 104

Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors

Saremi, A., Schwenke, D. C., Buchanan, T. A., Hodis, H. N., Mack, W. J., Banerji, M., Bray, G. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 101

Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study

Gastaldelli, A., Gaggini, M., Daniele, G., Ciociaro, D., Cersosimo, E., Tripathy, D., Triplitt, C., Fox, P., Musi, N., DeFronzo, R., et al. (2016) · Hepatology

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 96

Oxidative and non-oxidative glucose metabolism in non-obese Type 2 (non-insulin-dependent) diabetic patients

Golay, A., DeFronzo, R. A., Ferrannini, E., Simonson, D. C., Thorin, D., Acheson, K., Thi�baud, D., Curchod, B., J�quier, E., & Felber, J. P. (1988) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 91

The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance

Abdul-Ghani, M. A., Matsuda, M., Jani, R., Jenkinson, C. P., Coletta, D. K., Kaku, K., & DeFronzo, R. A. (2008) · American Journal of Physiology-Endocrinology and Metabolism

Pancreatic function and diabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 91